CURATIS N AG (CURN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CURATIS N AG (CURN) has a cash flow conversion efficiency ratio of -0.024x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-1.05 Million ≈ $-1.33 Million USD) by net assets (CHF44.56 Million ≈ $56.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CURATIS N AG market capitalisation for the company's overall valuation and market capitalisation.
CURATIS N AG - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how CURATIS N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CURATIS N AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CURATIS N AG ranked by their cash flow conversion efficiency. Explore earnings quality score of CURATIS N AG to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Finger Inc.
KQ:163730
|
0.073x |
|
Lion Selection Group Ltd
AU:LSX
|
-0.007x |
|
ImmuCell Corporation
NASDAQ:ICCC
|
0.096x |
|
BIOCELTIX S.A. ZY -10
F:XI3
|
-0.062x |
|
TDG Gold Corp
V:TDG
|
-0.226x |
|
Paseco Co. Ltd
KQ:037070
|
-0.036x |
|
Pearson PLC
LSE:PSON
|
0.129x |
|
Laster Tech Corp Ltd
TW:3346
|
0.159x |
Annual Cash Flow Conversion Efficiency for CURATIS N AG (2002–2024)
The table below shows the annual cash flow conversion efficiency of CURATIS N AG from 2002 to 2024. View CURATIS N AG (CURN) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF45.60 Million ≈ $57.65 Million |
CHF-825.00K ≈ $-1.04 Million |
-0.018x | -100.30% |
| 2023-12-31 | CHF-312.00K ≈ $-394.45K |
CHF-1.89 Million ≈ $-2.38 Million |
6.042x | +976.84% |
| 2022-12-31 | CHF6.75 Million ≈ $8.54 Million |
CHF-4.65 Million ≈ $-5.88 Million |
-0.689x | -176.77% |
| 2021-12-31 | CHF-400.00K ≈ $-505.71K |
CHF-359.00K ≈ $-453.87K |
0.898x | -38.98% |
| 2020-12-31 | CHF-257.00K ≈ $-324.92K |
CHF-378.00K ≈ $-477.89K |
1.471x | +22.64% |
| 2019-12-31 | CHF-552.00K ≈ $-697.88K |
CHF-662.00K ≈ $-836.95K |
1.199x | +160.36% |
| 2018-12-31 | CHF377.00K ≈ $476.63K |
CHF-749.00K ≈ $-946.94K |
-1.987x | -7596.73% |
| 2017-12-31 | CHF4.68 Million ≈ $5.92 Million |
CHF124.00K ≈ $156.77K |
0.027x | +273.50% |
| 2016-12-31 | CHF5.04 Million ≈ $6.37 Million |
CHF-77.00K ≈ $-97.35K |
-0.015x | +23.75% |
| 2015-12-31 | CHF6.24 Million ≈ $7.89 Million |
CHF-125.00K ≈ $-158.03K |
-0.020x | -34.08% |
| 2014-12-31 | CHF7.90 Million ≈ $9.99 Million |
CHF-118.00K ≈ $-149.18K |
-0.015x | +92.26% |
| 2013-12-31 | CHF8.71 Million ≈ $11.01 Million |
CHF-1.68 Million ≈ $-2.12 Million |
-0.193x | -445.52% |
| 2012-12-31 | CHF11.60 Million ≈ $14.67 Million |
CHF648.00K ≈ $819.25K |
0.056x | +32.82% |
| 2011-12-31 | CHF7.16 Million ≈ $9.05 Million |
CHF301.00K ≈ $380.55K |
0.042x | -82.42% |
| 2010-12-31 | CHF6.98 Million ≈ $8.82 Million |
CHF1.67 Million ≈ $2.11 Million |
0.239x | +41.54% |
| 2009-12-31 | CHF5.88 Million ≈ $7.44 Million |
CHF994.00K ≈ $1.26 Million |
0.169x | +105.69% |
| 2008-12-31 | CHF1.64 Million ≈ $2.08 Million |
CHF-4.88 Million ≈ $-6.16 Million |
-2.968x | +90.51% |
| 2007-12-31 | CHF227.00K ≈ $286.99K |
CHF-7.10 Million ≈ $-8.98 Million |
-31.282x | -10014.42% |
| 2006-12-31 | CHF9.30 Million ≈ $11.76 Million |
CHF-2.88 Million ≈ $-3.64 Million |
-0.309x | -27.63% |
| 2005-12-31 | CHF21.67 Million ≈ $27.40 Million |
CHF-5.25 Million ≈ $-6.64 Million |
-0.242x | -801.22% |
| 2004-12-31 | CHF37.30 Million ≈ $47.16 Million |
CHF1.29 Million ≈ $1.63 Million |
0.035x | +188.13% |
| 2003-12-31 | CHF49.83 Million ≈ $63.00 Million |
CHF-1.95 Million ≈ $-2.47 Million |
-0.039x | +89.09% |
| 2002-12-31 | CHF55.33 Million ≈ $69.96 Million |
CHF-19.88 Million ≈ $-25.13 Million |
-0.359x | -- |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more